{"favorite_id": 3009, "calc_type": "calculator", "dosing": false, "full_title_en": "UCLA Integrated Staging System (UISS) for Renal Cell Carcinoma (RCC)", "short_title_en": "UISS for RCC", "medium_description_en": "Provides 5-year disease-free prognosis for localized and metastatic RCC.", "short_description_en": "5 year prognosis for RCC.", "before_use": "", "instructions_en": "<ul> <li>Localized: Any T; N0; M0</li> <li>Metastatic: T>0; N>1; M>1</li> <li>For accurate staging, see the <calculator id='3011'> TNM Staging for RCC calculator</a></li></ul>", "purpose_en": ["Prognosis"], "disease_en": ["Renal Cell Carcinoma"], "specialty_en": ["Hematology and Oncology", "Hospitalist Medicine", "Internal Medicine", "Nephrology", "Urology"], "chief_complaint_en": ["Flank Pain", "Hematuria"], "system_en": ["Oncologic", "Renal", "Urinary"], "search_abbreviation_en": ["UCLA", "RCC", "localized", "mets", "metastatic", "UISS"], "slug": "ucla-integrated-staging-system-uiss-renal-cell-carcinoma-rcc", "seo": {"meta_description_en": "UCLA Integrated Staging System (UISS) for Renal Cell Carcinoma (RCC) provides 5-year disease-free prognosis for localized and metastatic RCC.", "keywords_en": "ucla, ucla score, rcc score, uiss score, ucla uiss score, rcc prognosis, ucla cancer score, ucla cancer prognosis, ucla rcc score, renal cell carcinoma score, ucla kidney cancer, kidney cancer score, metastatic rcc, localized rcc, tnm rcc, tnm ucla, tnm UISS, UCLA UISS"}, "content": {"how_to_use": {"use_case_en": "<p>Patients with RCC, localized or metastatic, particularly those being considered for clinical trial enrollment.</p>", "pearls_pitfalls_en": "<ul> <li>This score placed patients with local or metastatic renal cell carcinoma (mRCC) into mortality risk groups: low, intermediate/moderate, and high.</li> <li>The derivation and numerous external validations have been chart reviews, though all find orderly progressions in 5-year survival based on group.</li> <li>Prospective validation is eagerly awaited, and we know of no validations including substantial numbers of patients treated with modern targeted VEGF therapy.</li> </ul>", "why_use_en": "<p>There are no validated scoring systems for predicting survival in mRCC. Using a score may help sketch categories of survival time better than clinical judgment alone.</p>"}, "next_steps": {"advice_en": "<p>The UISS score is often used for screening and stratifying patients into modern therapy trials, including trials of VEGF therapy such as SUNItinib. The consistency of results in validation studies is somewhat reassuring, and one advantage is its applicability to patients with and without metastatic disease.</p>", "management_en": "<ul>\n<li>We are unaware of validated management algorithms using the score.</li>\n<li>Refer to&nbsp;<guideline id=\"10121\">AUA guidelines</guideline>&nbsp;for management of renal cancer.</li>\n</ul>", "critical_actions_en": "<p>The UISS score is complex, requiring close attention to multiple variables for correct classification.</p>"}, "about": {"formula_en": "<p>Addition of the selected points:</p> <p><strong>Localized disease (Any T, N0M0)</strong></p> <table> <tbody> <tr> <td> <p><strong>T stage</strong></p> </td> <td> <p><strong><calculator id='3012'>Nuclear grade</calculator></strong></p> </td> <td> <p><strong><calculator id='3170'>ECOG PS</calculator></strong></p> </td> <td> <p><strong>Risk</strong></p> </td> </tr> <tr> <td rowspan=\"3\"> <p>T1</p> </td> <td rowspan=\"2\"> <p>Fuhrman 1-2</p> </td> <td> <p>0</p> </td> <td> <p>Low</p> </td> </tr> <tr> <td> <p>\u22651</p> </td> <td rowspan=\"6\"> <p>Intermediate</p> </td> </tr> <tr> <td> <p>Fuhrman 3-4</p> </td> <td> <p>Any</p> </td> </tr> <tr> <td> <p>T2</p> </td> <td> <p>Any</p> </td> <td> <p>Any</p> </td> </tr> <tr> <td rowspan=\"4\"> <p>T3</p> </td> <td rowspan=\"2\"> <p>Fuhrman 1</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>\u22651</p> </td> </tr> <tr> <td rowspan=\"2\"> <p>Fuhrman &gt;1</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>\u22651</p> </td> <td> <p>High</p> </td> </tr> </tbody> </table> <p><strong><br>Metastatic disease (N1, N2, or M1)</strong></p> <table> <tbody> <tr> <td> <p><strong>N/M stage</strong></p> </td> <td> <p><strong><calculator id='3012'>Nuclear grade</calculator></strong></p> </td> <td> <p><strong><calculator id='3170'>ECOG PS</calculator></strong></p> </td> <td> <p><strong>Risk</strong></p> </td> </tr> <tr> <td> <p>N1M0</p> </td> <td> <p>Any</p> </td> <td> <p>Any</p> </td> <td> <p>Low</p> </td> </tr> <tr> <td rowspan=\"7\"> <p>N2M0/M1</p> </td> <td rowspan=\"2\"> <p>Fuhrman 1</p> </td> <td> <p>0</p> </td> <td> <p>Low</p> </td> </tr> <tr> <td> <p>\u22651</p> </td> <td> <p>Intermediate</p> </td> </tr> <tr> <td rowspan=\"2\"> <p>Fuhrman 2</p> </td> <td> <p>0</p> </td> <td> <p>Low</p> </td> </tr> <tr> <td> <p>\u22651</p> </td> <td rowspan=\"3\"> <p>Intermediate</p> </td> </tr> <tr> <td> <p>Fuhrman 3</p> </td> <td> <p>Any</p> </td> </tr> <tr> <td rowspan=\"2\"> <p>Fuhrman 4</p> </td> <td> <p>0</p> </td> </tr> <tr> <td> <p>\u22651</p> </td> <td> <p>High</p> </td> </tr> </tbody> </table> <p>&nbsp;</p>", "more_info_en": "<div class='table-responsive'> <table class='table table-bordered table-hover'> <tbody> <tr> <th>Disease Type</th> <th>Risk Group</th> <th>Five-year disease-specific survival</th> </tr> <tr> <td rowspan='3'>Local Disease</td> <td>Low</td> <td>91.1%</td> </tr> <tr> <td>Intermediate</td> <td>80.4%</td> </tr> <tr> <td>High</td> <td>54.7%</td> </tr> <tr> <td rowspan='3'>Metastatic Disease</td> <td>Low</td> <td>32%</td> </tr> <tr> <td>Intermediate</td> <td>19.5%</td> </tr> <tr> <td>High</td> <td>0%</td> </tr> </tbody> </table> </div>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/12454113", "text": "Zisman A,Pantuck AJ,Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20: 4559\u20134566."}], "Other References": [{"href": "http://annonc.oxfordjournals.org/content/23/suppl_7/vii65.full", "text": "Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012; 23(suppl 7):vii65\u2013vii71."}], "Validation": [{"href": "http://jco.ascopubs.org/content/22/16/3316.abstract?ijkey=a1a6e4e6960a768fd1f4bfbde97f0aae0810e1ca&keytype2=tf_ipsecsha", "text": "Patard J, et al. Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study. JCO Aug 15, 2004:3316-3322"}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Amnon Zisman", "creator_info": {"deceased": null, "about_en": "<p>Amnon Zisman, MD, is professor of urologic surgery at Sackler School of Medicine affiliated Tel Aviv University. He is currently head of urology department at Assaf Harofeh Medical Center. Dr. Zisman\u2019s research focuses on increased accuracy of diagnosis and prognosis of RCC as well as novel treatment strategies in renal disease.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-amnon-zisman.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Zisman+A%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [{"society": "American Urological Association", "link": "https://www.mdcalc.com/guidelines/other/renal-mass-localized-renal-cancer", "text": "Renal Mass and Localized Renal Cancer", "description": "Guideline from AUA"}], "teaching": [], "videos": [], "interests": [{"link": "https://www.mdcalc.com/rcc-renal-cell-carcinoma-practice-pearls", "text": "Practice Pearls: Renal Cell Carcinoma"}], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Type of disease present", "name": "disease", "options": [{"label": "Metastatic", "value": 2}, {"label": "Localized", "value": 1}], "conditionality": "", "show_points": false, "optional": false}, {"type": "subheading", "subheading": "UISS Criteria", "subheading_instructions": ""}, {"type": "radio", "label_en": "Localized disease - T stage", "name": "t", "options": [{"label": "T1", "value": 1}, {"label": "T2", "value": 2}, {"label": "T3", "value": 3}, {"label": "T4", "value": 4}], "conditionality": "disease == 1", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Metastatic disease - N stage", "name": "n", "options": [{"label": "N1", "value": 1}, {"label": "N2", "value": 2}], "conditionality": "disease == 2", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Metastatic disease - M stage", "name": "m", "options": [{"label": "M0", "value": 0}, {"label": "M1", "value": 1}], "conditionality": "disease == 2", "show_points": false, "optional": false}, {"type": "radio", "label_en": "<calculator id='3012'>Fuhrman nuclear grade</calculator>", "name": "fuhrman", "options": [{"label": "I", "value": 1}, {"label": "II", "value": 2}, {"label": "III", "value": 3}, {"label": "IV", "value": 4}], "conditionality": "", "show_points": false, "optional": false}, {"type": "radio", "label_en": "<calculator id='3170'>ECOG Performance Status</calculator>", "name": "ecog", "options": [{"label": "0", "value": 0}, {"label": "\u22651", "value": 1}], "conditionality": "", "show_points": false, "optional": false}], "md5": "822adfbc348175af5eeb230bb7070d24", "related_calcs": [{"calcId": 3012, "short_title_en": "Fuhrman Nuclear Grade", "slug": "fuhrman-nuclear-grade-clear-cell-renal-carcinoma"}, {"calcId": 3008, "short_title_en": "IMDC Model for mRCC", "slug": "imdc-international-metastatic-rcc-database-consortium-risk-model-metastatic-renal-cell-carcinoma"}, {"calcId": 3007, "short_title_en": "Mekhail Extension", "slug": "mekhail-extension-motzer-score"}]}